<?xml version="1.0" encoding="utf-8"?>
<rss 
  version="2.0">
  <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/">
    <title>Theratechnologies</title>
    <link>https://www.globenewswire.com/rssfeed/organization/43DBdSHILPUb89d7_NI6RQ==</link>
    <description>Contains the last 20 releases</description>
    <copyright>Copyright 2024, Theratechnologies</copyright>
    <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor>
    <lastBuildDate>Thu, 17 Oct 2024 18:00:00 GMT</lastBuildDate>
    <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/17/2965162/0/en/Theratechnologies-IDWeek-Presentations-Highlight-the-Impact-of-Excess-Visceral-Abdominal-Fat-EVAF-on-Cardiovascular-Disease-CVD-Risk-in-People-with-HIV.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/10/17/2965162/0/en/Theratechnologies-IDWeek-Presentations-Highlight-the-Impact-of-Excess-Visceral-Abdominal-Fat-EVAF-on-Cardiovascular-Disease-CVD-Risk-in-People-with-HIV.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV</title>
      <description><![CDATA[Data Show Tesamorelin May Reduce CVD Risk by Reducing EVAF <pre>Data Show Tesamorelin May Reduce CVD Risk by Reducing EVAF</pre>]]></description>
      <pubDate>Thu, 17 Oct 2024 18:00 GMT</pubDate>
      <dc:identifier>2965162</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Thu, 17 Oct 2024 18:00 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Clinical Study</dc:subject>
      <dc:keyword>EVAF</dc:keyword>
      <dc:keyword>tesamorelin</dc:keyword>
      <dc:keyword>CVD</dc:keyword>
      <dc:keyword>IDWeek2024</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/17/2965162/0/fr/Les-pr%C3%A9sentations-de-Theratechnologies-lors-de-l-IDWeek-mettent-en-%C3%A9vidence-l-incidence-de-l-exc%C3%A8s-de-graisse-visc%C3%A9rale-abdominale-sur-le-risque-de-maladie-cardiovasculaire-chez-le.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/10/17/2965162/0/fr/Les-pr%C3%A9sentations-de-Theratechnologies-lors-de-l-IDWeek-mettent-en-%C3%A9vidence-l-incidence-de-l-exc%C3%A8s-de-graisse-visc%C3%A9rale-abdominale-sur-le-risque-de-maladie-cardiovasculaire-chez-le.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Les présentations de Theratechnologies lors de l’IDWeek mettent en évidence l’incidence de l’excès de graisse viscérale abdominale sur le risque de maladie cardiovasculaire chez les personnes vivant avec le VIH</title>
      <description><![CDATA[Selon les données, la tésamoréline pourrait réduire le risque de maladie cardiovasculaire en diminuant l’excès de graisse viscérale abdominale <pre>Selon les données, la tésamoréline pourrait réduire le risque de maladie cardiovasculaire en diminuant l’excès de graisse viscérale abdominale</pre>]]></description>
      <pubDate>Thu, 17 Oct 2024 18:00 GMT</pubDate>
      <dc:identifier>2965162</dc:identifier>
      <dc:language>fr</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Thu, 17 Oct 2024 18:00 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Clinical Study</dc:subject>
      <dc:keyword>EVAF</dc:keyword>
      <dc:keyword>tesamorelin</dc:keyword>
      <dc:keyword>CVD</dc:keyword>
      <dc:keyword>IDWeek2024</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/17/2964771/0/en/Theratechnologies-Unveils-Study-Design-and-Baseline-Characteristics-of-PROMISE-US-Trial-of-Ibalizumab-in-Heavily-Treatment-Experienced-People-with-HIV-and-Multidrug-Resistance.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/10/17/2964771/0/en/Theratechnologies-Unveils-Study-Design-and-Baseline-Characteristics-of-PROMISE-US-Trial-of-Ibalizumab-in-Heavily-Treatment-Experienced-People-with-HIV-and-Multidrug-Resistance.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance</title>
      <description><![CDATA[Baseline Data Show More Frequent Selection of Ibalizumab in Patients with Lower CD4 Counts and Higher Viral Loads, Compared to Other Regimens <pre>Baseline Data Show More Frequent Selection of Ibalizumab in Patients with Lower CD4 Counts and Higher Viral Loads, Compared to Other Regimens</pre>]]></description>
      <pubDate>Thu, 17 Oct 2024 11:30 GMT</pubDate>
      <dc:identifier>2964771</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Thu, 17 Oct 2024 11:30 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Clinical Study</dc:subject>
      <dc:keyword>IDWeek2024</dc:keyword>
      <dc:keyword>multi-drug resistant</dc:keyword>
      <dc:keyword>ibalizumab</dc:keyword>
      <dc:keyword>heavily treatment-experienced</dc:keyword>
      <dc:keyword>HIV</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/17/2964771/0/fr/Theratechnologies-d%C3%A9voile-le-plan-et-les-caract%C3%A9ristiques-initiales-de-l-essai-PROMISE-US-sur-l-ibalizumab-chez-les-personnes-vivant-avec-le-VIH-ayant-re%C3%A7u-de-nombreux-traitements-.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/10/17/2964771/0/fr/Theratechnologies-d%C3%A9voile-le-plan-et-les-caract%C3%A9ristiques-initiales-de-l-essai-PROMISE-US-sur-l-ibalizumab-chez-les-personnes-vivant-avec-le-VIH-ayant-re%C3%A7u-de-nombreux-traitements-.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies dévoile le plan et les caractéristiques initiales de l'essai PROMISE-US sur l'ibalizumab chez les personnes vivant avec le VIH ayant reçu de nombreux traitements et présentant une multirésistance aux médicaments</title>
      <description><![CDATA[Les données initiales démontrent que l’ibalizumab est sélectionné plus souvent que les autres traitements chez les patients présentant un nombre de lymphocytes CD4 plus faible et une charge virale plus élevée <pre>Les données initiales démontrent que l’ibalizumab est sélectionné plus souvent que les autres traitements chez les patients présentant un nombre de lymphocytes CD4 plus faible et une charge virale plus élevée</pre>]]></description>
      <pubDate>Thu, 17 Oct 2024 11:30 GMT</pubDate>
      <dc:identifier>2964771</dc:identifier>
      <dc:language>fr</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Thu, 17 Oct 2024 11:30 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Clinical Study</dc:subject>
      <dc:keyword>IDWeek2024</dc:keyword>
      <dc:keyword>multi-drug resistant</dc:keyword>
      <dc:keyword>ibalizumab</dc:keyword>
      <dc:keyword>heavily treatment-experienced</dc:keyword>
      <dc:keyword>HIV</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/10/2961209/0/en/Theratechnologies-Reports-Strong-Financial-Results-and-Announces-Positive-Net-Income-for-Third-Quarter-2024.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/10/10/2961209/0/en/Theratechnologies-Reports-Strong-Financial-Results-and-Announces-Positive-Net-Income-for-Third-Quarter-2024.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024</title>
      <description><![CDATA[<p align="justify">MONTREAL, Oct.  10, 2024  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2024 ended August 31, 2024 (Q3 2024). All figures are in US dollars unless otherwise stated.</p>]]></description>
      <pubDate>Thu, 10 Oct 2024 11:30 GMT</pubDate>
      <dc:identifier>2961209</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Thu, 10 Oct 2024 11:30 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Earnings Releases and Operating Results</dc:subject>
      <dc:subject>Conference Calls/ Webcasts</dc:subject>
      <dc:keyword>Q3 Earnings</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/10/2961209/0/fr/Theratechnologies-pr%C3%A9sente-de-solides-r%C3%A9sultats-financiers-et-annonce-un-r%C3%A9sultat-net-positif-pour-le-troisi%C3%A8me-trimestre-de-l-exercice-2024.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/10/10/2961209/0/fr/Theratechnologies-pr%C3%A9sente-de-solides-r%C3%A9sultats-financiers-et-annonce-un-r%C3%A9sultat-net-positif-pour-le-troisi%C3%A8me-trimestre-de-l-exercice-2024.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies présente de solides résultats financiers et annonce un résultat net positif pour le troisième trimestre de l’exercice 2024</title>
      <description><![CDATA[<p align="justify">MONTR&#201;AL,  10 oct. 2024  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies », ou la « Société ») (TSX : TH) (NASDAQ : THTX), société biopharmaceutique dont les activités sont axées sur le développement et la commercialisation de traitements novateurs, a présenté aujourd’hui ses faits saillants commerciaux et ses résultats financiers pour le troisième trimestre de l’exercice 2024, clos le 31 août 2024 (le « troisième trimestre de l’exercice 2024 », ou « T3 2024 »). Sauf indication contraire, tous les montants sont présentés en dollars américains.</p>]]></description>
      <pubDate>Thu, 10 Oct 2024 11:30 GMT</pubDate>
      <dc:identifier>2961209</dc:identifier>
      <dc:language>fr</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Thu, 10 Oct 2024 11:30 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Earnings Releases and Operating Results</dc:subject>
      <dc:subject>Conference Calls/ Webcasts</dc:subject>
      <dc:keyword>Q3 Earnings</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/09/2960418/0/en/Theratechnologies-to-Present-Data-at-IDWeek-2024-Highlighting-Advances-in-Treatment-and-Management-of-Complications-in-People-with-HIV.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/10/09/2960418/0/en/Theratechnologies-to-Present-Data-at-IDWeek-2024-Highlighting-Advances-in-Treatment-and-Management-of-Complications-in-People-with-HIV.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV</title>
      <description><![CDATA[<p align="justify">MONTREAL, Oct.  09, 2024  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and commercialization of innovative therapies, today announced three upcoming poster presentations at IDWeek 2024, taking place October 16-19 in Los Angeles, Calif.<br></p>]]></description>
      <pubDate>Wed, 09 Oct 2024 11:30 GMT</pubDate>
      <dc:identifier>2960418</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Wed, 09 Oct 2024 11:30 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:keyword>IDWeek2024</dc:keyword>
      <dc:keyword>HIV</dc:keyword>
      <dc:keyword>EVAF</dc:keyword>
      <dc:keyword>tesamorelin</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/09/2960418/0/fr/Theratechnologies-pr%C3%A9sentera-des-donn%C3%A9es-%C3%A0-l-IDWeek-2024-soulignant-les-progr%C3%A8s-r%C3%A9alis%C3%A9s-dans-le-traitement-et-la-prise-en-charge-des-complications-chez-les-personnes-vivant-avec-l.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/10/09/2960418/0/fr/Theratechnologies-pr%C3%A9sentera-des-donn%C3%A9es-%C3%A0-l-IDWeek-2024-soulignant-les-progr%C3%A8s-r%C3%A9alis%C3%A9s-dans-le-traitement-et-la-prise-en-charge-des-complications-chez-les-personnes-vivant-avec-l.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies présentera des données à l’IDWeek 2024 soulignant les progrès réalisés dans le traitement et la prise en charge des complications chez les personnes vivant avec le VIH</title>
      <description><![CDATA[<p align="justify">MONTR&#201;AL,  09 oct. 2024  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au point et la commercialisation de traitements novateurs, a annoncé aujourd’hui trois présentations d’affiches à venir lors de la conférence IDWeek 2024, qui aura lieu du 16 au 19 octobre à Los Angeles, en Californie.<br></p>]]></description>
      <pubDate>Wed, 09 Oct 2024 11:30 GMT</pubDate>
      <dc:identifier>2960418</dc:identifier>
      <dc:language>fr</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Wed, 09 Oct 2024 11:30 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:keyword>IDWeek2024</dc:keyword>
      <dc:keyword>HIV</dc:keyword>
      <dc:keyword>EVAF</dc:keyword>
      <dc:keyword>tesamorelin</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/26/2953701/0/en/Theratechnologies-to-Announce-Third-Quarter-2024-Financial-Results-and-Provide-Business-Update.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/09/26/2953701/0/en/Theratechnologies-to-Announce-Third-Quarter-2024-Financial-Results-and-Provide-Business-Update.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update</title>
      <description><![CDATA[<p align="justify">MONTREAL, Sept.  26, 2024  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third quarter ended August 31, 2024, on Thursday, October 10 at 8:30 a.m. ET.<br></p>]]></description>
      <pubDate>Thu, 26 Sep 2024 11:30 GMT</pubDate>
      <dc:identifier>2953701</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Thu, 26 Sep 2024 11:30 GMT</dc:modified>
      <dc:subject>Earnings Releases and Operating Results</dc:subject>
      <dc:subject>Conference Calls/ Webcasts</dc:subject>
      <dc:keyword>Q3 Earnings</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/26/2953701/0/fr/Theratechnologies-annoncera-ses-r%C3%A9sultats-financiers-du-troisi%C3%A8me-trimestre-de-l-exercice-financier-de-2024-et-fera-une-mise-%C3%A0-jour-de-ses-activit%C3%A9s.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/09/26/2953701/0/fr/Theratechnologies-annoncera-ses-r%C3%A9sultats-financiers-du-troisi%C3%A8me-trimestre-de-l-exercice-financier-de-2024-et-fera-une-mise-%C3%A0-jour-de-ses-activit%C3%A9s.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies annoncera ses résultats financiers du troisième trimestre de l’exercice financier de 2024 et fera une mise à jour de ses activités</title>
      <description><![CDATA[<p align="justify">MONTR&#201;AL,  26 sept. 2024  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique axée sur le développement et la commercialisation de traitements innovateurs, annonce aujourd’hui que la Société dévoilera ses résultats pour le troisième trimestre de l’exercice financier de 2024, clos le 31 août 2024, et fera le point sur ses activités, le jeudi 10 octobre, à 8 h 30 (HE).<br></p>]]></description>
      <pubDate>Thu, 26 Sep 2024 11:30 GMT</pubDate>
      <dc:identifier>2953701</dc:identifier>
      <dc:language>fr</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Thu, 26 Sep 2024 11:30 GMT</dc:modified>
      <dc:subject>Earnings Releases and Operating Results</dc:subject>
      <dc:subject>Conference Calls/ Webcasts</dc:subject>
      <dc:keyword>Q3 Earnings</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/17/2947862/0/en/Theratechnologies-Announces-a-Risk-of-a-Temporary-Supply-Disruption-for-EGRIFTA-SV-in-Early-2025.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/09/17/2947862/0/en/Theratechnologies-Announces-a-Risk-of-a-Temporary-Supply-Disruption-for-EGRIFTA-SV-in-Early-2025.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025</title>
      <description><![CDATA[<p align="justify">MONTREAL, Sept.  17, 2024  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced a risk of a temporary supply disruption for <em>EGRIFTA SV</em><sup>®</sup> (tesamorelin for injection) in early 2025 caused by an unexpected voluntary shutdown of the Company’s contract manufacturer’s facility following an inspection by the US Food and Drug Administration (FDA), as well as the FDA review timeline to resume distribution of the product.<br></p>]]></description>
      <pubDate>Tue, 17 Sep 2024 21:00 GMT</pubDate>
      <dc:identifier>2947862</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Tue, 17 Sep 2024 21:00 GMT</dc:modified>
      <dc:subject>Product / Services Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/17/2947862/0/fr/Theratechnologies-annonce-un-risque-d-interruption-temporaire-de-l-approvisionnement-d-EGRIFTA-SV%E1%B4%B9%E1%B4%B0-au-d%C3%A9but-de-2025.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/09/17/2947862/0/fr/Theratechnologies-annonce-un-risque-d-interruption-temporaire-de-l-approvisionnement-d-EGRIFTA-SV%E1%B4%B9%E1%B4%B0-au-d%C3%A9but-de-2025.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies annonce un risque d’interruption temporaire de l’approvisionnement d’EGRIFTA SVᴹᴰ au début de 2025</title>
      <description><![CDATA[<p align="justify">MONTR&#201;AL,  17 sept. 2024  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au point et la commercialisation de traitements novateurs, a annoncé aujourd’hui un risque d’interruption temporaire de l’approvisionnement d’<em>EGRIFTA SV</em><sup>MD</sup> (tésamoréline pour injection) au début de 2025, en raison d’une fermeture volontaire inattendue des installations de son fabricant contractuel de l’entreprise à la suite d’une inspection par la <em>Food and Drug Administration</em> (FDA) des États-Unis et du délai d’examen de la FDA pour la reprise de la distribution du produit.<br></p>]]></description>
      <pubDate>Tue, 17 Sep 2024 21:00 GMT</pubDate>
      <dc:identifier>2947862</dc:identifier>
      <dc:language>fr</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Tue, 17 Sep 2024 21:00 GMT</dc:modified>
      <dc:subject>Product / Services Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/09/2942713/0/en/Theratechnologies-to-Present-at-Upcoming-Investor-Conferences-in-September.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/09/09/2942713/0/en/Theratechnologies-to-Present-at-Upcoming-Investor-Conferences-in-September.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies to Present at Upcoming Investor Conferences in September</title>
      <description><![CDATA[<p align="justify">MONTREAL, Sept.  09, 2024  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company’s President and CEO, Paul Lévesque will be presenting at two investor conferences in September. Members of the Theratechnologies management team will also be available for one-on-one meetings throughout the conferences.<br></p>]]></description>
      <pubDate>Mon, 09 Sep 2024 11:30 GMT</pubDate>
      <dc:identifier>2942713</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Mon, 09 Sep 2024 11:30 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:keyword>HC Wainwright conference</dc:keyword>
      <dc:keyword>Cantor Conference</dc:keyword>
      <dc:keyword>Investor Presentation</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/09/2942713/0/fr/Theratechnologies-fera-des-pr%C3%A9sentations-aux-conf%C3%A9rences-d-investisseurs-en-septembre.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/09/09/2942713/0/fr/Theratechnologies-fera-des-pr%C3%A9sentations-aux-conf%C3%A9rences-d-investisseurs-en-septembre.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies fera des présentations aux conférences d'investisseurs en septembre</title>
      <description><![CDATA[<p align="justify">MONTR&#201;AL,  09 sept. 2024  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au point et la commercialisation de traitements novateurs, a annoncé aujourd’hui que son président et chef de la direction, Paul Lévesque présentera l’entreprise et ses réalisations lors de deux conférences d'investisseurs en septembre. Des membres de l'équipe de direction de Theratechnologies participeront également à des rencontres tout au long des conférences.</p>]]></description>
      <pubDate>Mon, 09 Sep 2024 11:30 GMT</pubDate>
      <dc:identifier>2942713</dc:identifier>
      <dc:language>fr</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Mon, 09 Sep 2024 11:30 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:keyword>HC Wainwright conference</dc:keyword>
      <dc:keyword>Cantor Conference</dc:keyword>
      <dc:keyword>Investor Presentation</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/07/10/2911025/0/en/Theratechnologies-Reports-Financial-Results-and-Announces-Positive-Net-Income-for-Second-Quarter-2024.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/07/10/2911025/0/en/Theratechnologies-Reports-Financial-Results-and-Announces-Positive-Net-Income-for-Second-Quarter-2024.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024</title>
      <description><![CDATA[<p align="justify">MONTREAL, July  10, 2024  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter of fiscal year 2024 ended May 31, 2024 (Q2 2024). All figures are in US dollars unless otherwise stated.<br></p>]]></description>
      <pubDate>Wed, 10 Jul 2024 11:30 GMT</pubDate>
      <dc:identifier>2911025</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Wed, 10 Jul 2024 11:30 GMT</dc:modified>
      <dc:subject>Earnings Releases and Operating Results</dc:subject>
      <dc:keyword>Q22024</dc:keyword>
      <dc:keyword>Earnings</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/07/10/2911025/0/fr/Theratechnologies-pr%C3%A9sente-ses-r%C3%A9sultats-financiers-et-annonce-un-b%C3%A9n%C3%A9fice-net-positif-pour-le-deuxi%C3%A8me-trimestre-de-l-exercice-2024.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/07/10/2911025/0/fr/Theratechnologies-pr%C3%A9sente-ses-r%C3%A9sultats-financiers-et-annonce-un-b%C3%A9n%C3%A9fice-net-positif-pour-le-deuxi%C3%A8me-trimestre-de-l-exercice-2024.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies présente ses résultats financiers et annonce un bénéfice net positif pour le deuxième trimestre de l’exercice 2024</title>
      <description><![CDATA[<p align="justify">MONTR&#201;AL,  10 juill. 2024  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies », ou la « Société ») (TSX : TH) (NASDAQ : THTX), société biopharmaceutique dont les activités sont axées sur le développement et la commercialisation de traitements novateurs, a présenté aujourd’hui ses faits saillants commerciaux et ses résultats financiers pour le deuxième trimestre de l’exercice 2024, clos le 31 mai 2024 (le « deuxième trimestre de l’exercice 2024, ou « T2 2024 »). Sauf indication contraire, tous les montants sont présentés en dollars américains. <br></p>]]></description>
      <pubDate>Wed, 10 Jul 2024 11:30 GMT</pubDate>
      <dc:identifier>2911025</dc:identifier>
      <dc:language>fr</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Wed, 10 Jul 2024 11:30 GMT</dc:modified>
      <dc:subject>Earnings Releases and Operating Results</dc:subject>
      <dc:keyword>Q22024</dc:keyword>
      <dc:keyword>Earnings</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/06/26/2904408/0/en/Theratechnologies-to-Announce-Second-Quarter-2024-Financial-Results-and-Provide-Business-Update.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/06/26/2904408/0/en/Theratechnologies-to-Announce-Second-Quarter-2024-Financial-Results-and-Provide-Business-Update.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update</title>
      <description><![CDATA[<p align="justify">MONTREAL, June  26, 2024  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its second quarter ended May 31, 2024, on Wednesday, July 10 at 8:30 a.m. ET.<br></p>]]></description>
      <pubDate>Wed, 26 Jun 2024 11:30 GMT</pubDate>
      <dc:identifier>2904408</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Wed, 26 Jun 2024 11:30 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:keyword>Earnings Call</dc:keyword>
      <dc:keyword>Q2</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/06/26/2904408/0/fr/Theratechnologies-annoncera-ses-r%C3%A9sultats-financiers-du-deuxi%C3%A8me-trimestre-de-l-exercice-financier-de-2024-et-fera-une-mise-%C3%A0-jour-de-ses-activit%C3%A9s.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/06/26/2904408/0/fr/Theratechnologies-annoncera-ses-r%C3%A9sultats-financiers-du-deuxi%C3%A8me-trimestre-de-l-exercice-financier-de-2024-et-fera-une-mise-%C3%A0-jour-de-ses-activit%C3%A9s.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies annoncera ses résultats financiers du deuxième trimestre de l’exercice financier de 2024 et fera une mise à jour de ses activités</title>
      <description><![CDATA[<p align="justify">MONTR&#201;AL,  26 juin 2024  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique axée sur le développement et la commercialisation de traitements innovateurs, annonce aujourd’hui que la Société dévoilera ses résultats pour le deuxième trimestre de l’exercice financier de 2024, clos le 31 mai 2024, et fera le point sur ses activités, le mercredi 10 juillet 2024, à 8 h 30 (HE).<br></p>]]></description>
      <pubDate>Wed, 26 Jun 2024 11:30 GMT</pubDate>
      <dc:identifier>2904408</dc:identifier>
      <dc:language>fr</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Wed, 26 Jun 2024 11:30 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:keyword>Earnings Call</dc:keyword>
      <dc:keyword>Q2</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/05/23/2887682/0/en/Theratechnologies-Sudocetaxel-Zendusortide-ASCO-2024-Presentation-Demonstrates-Signs-of-Long-Term-Efficacy-and-Manageable-Safety-Profile-in-Patients-with-Solid-Tumors.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/05/23/2887682/0/en/Theratechnologies-Sudocetaxel-Zendusortide-ASCO-2024-Presentation-Demonstrates-Signs-of-Long-Term-Efficacy-and-Manageable-Safety-Profile-in-Patients-with-Solid-Tumors.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors</title>
      <description><![CDATA[<p align="justify">MONTREAL, May  23, 2024  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced Phase 1 data demonstrating signs of long-term efficacy and a manageable safety profile of its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902), in patients with solid tumors. The data will be presented in a <a href="https://www.globenewswire.com/Tracker?data=gw9rlW-UA9PwqFERN8Uia-7R6LMDxo-3feY9Oo1NOHn8uC8X-iPXizFDQZs4yp9_CpqN3PtrpY_0L8xcREayAX_Ek8jxkatweASFZekYcbLddakPKr3SDhJ0SJu1CNFEZEnqYxf1jTXwAFITmLXM2p6LTw85pLXjposUEfrVypPbV5cmz_qUx9MgJaITmUIDIKXv68-0Y9jhF4cSFhg8_g==" rel="nofollow" target="_blank" title="poster session">poster session</a> on June 1, 9:00 AM-12:00 PM CDT (abstract #3081, poster board #226) at the 2024 American Society of Clinical Oncology (ASCO) annual meeting, which is taking place May 31-June 4, 2024, in Chicago, IL.</p>]]></description>
      <pubDate>Thu, 23 May 2024 21:00 GMT</pubDate>
      <dc:identifier>2887682</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Thu, 23 May 2024 21:00 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Health</dc:subject>
      <dc:subject>Trade Show</dc:subject>
      <dc:keyword>ASCO2024</dc:keyword>
      <dc:keyword>Oncology</dc:keyword>
      <dc:keyword>PDC</dc:keyword>
      <dc:keyword>TH1902</dc:keyword>
      <dc:keyword>solid tumors</dc:keyword>
      <dc:keyword>oncologie</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/05/23/2887682/0/fr/Theratechnologies-fait-une-pr%C3%A9sentation-sur-le-sudoc%C3%A9taxel-zendusortide-au-Congr%C3%A8s-2024-de-l-ASCO-qui-montre-des-signes-d-une-efficacit%C3%A9-%C3%A0-long-terme-et-un-profil-d-innocuit%C3%A9-g%C3%A9rab.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/05/23/2887682/0/fr/Theratechnologies-fait-une-pr%C3%A9sentation-sur-le-sudoc%C3%A9taxel-zendusortide-au-Congr%C3%A8s-2024-de-l-ASCO-qui-montre-des-signes-d-une-efficacit%C3%A9-%C3%A0-long-terme-et-un-profil-d-innocuit%C3%A9-g%C3%A9rab.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:TH</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:THTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA88338H1001</category>
      <title>Theratechnologies fait une présentation sur le sudocétaxel zendusortide au Congrès 2024 de l’ASCO qui montre des signes d’une efficacité à long terme et un profil d’innocuité gérable chez les patients atteints de tumeurs solides</title>
      <description><![CDATA[<p align="justify">MONTR&#201;AL,  23 mai 2024  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au point et la commercialisation de traitements novateurs, a annoncé aujourd’hui des données de phase I établissant des signes d’efficacité à long terme et un profil d’innocuité gérable de son principal conjugué peptide-médicament (CPM) expérimental, le sudocétaxel zendusortide (TH1902), dans le traitement de patients atteints de tumeurs solides. Les données seront présentées dans le cadre d’une <a href="https://www.globenewswire.com/Tracker?data=zbe1WMH0vPiqFf8zqXju-IxHS3LIG6VZTWSSRyK4ltIlhyrSAEnbUz-O26FaY_DzrQoLvElccsiVw7vdeQ7Ru_NZFERrk_m8b8aM_znlWBT0DI-3ybRwHYBJF7K3p5-mBtAroc5VV1lAxBbiqU8ArWPm--kDtfH11B9Gvj3SO2UpNLoh3JBa7FAJTdZUnT5Peq--jGzvFzfZYcPTOiJqun5sXv5PFS99sC_7VkhwqoY=" rel="nofollow" target="_blank" title="séance d’affiches">séance d’affiches</a> le 1<sup>er</sup> juin, de 9 h à 12 h (HAC) (résumé n<sup>o</sup> 3081, panneau d’affichage n<sup>o</sup> 226) au Congrès 2024 de l’ASCO (American Society of Clinical Oncology) qui aura lieu du 31 mai au 4 juin 2024, à Chicago (Illinois).</p>]]></description>
      <pubDate>Thu, 23 May 2024 21:00 GMT</pubDate>
      <dc:identifier>2887682</dc:identifier>
      <dc:language>fr</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Theratechnologies</dc:contributor>
      <dc:modified>Thu, 23 May 2024 21:00 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Health</dc:subject>
      <dc:subject>Trade Show</dc:subject>
      <dc:keyword>ASCO2024</dc:keyword>
      <dc:keyword>Oncology</dc:keyword>
      <dc:keyword>PDC</dc:keyword>
      <dc:keyword>TH1902</dc:keyword>
      <dc:keyword>solid tumors</dc:keyword>
      <dc:keyword>oncologie</dc:keyword>
    </item>
  </channel>
</rss>